Kaleidex One will strengthen UK medtech manufacturing capability with advanced automation, cleanroom capacity, and end-to-end production solutions
[Leeds, 14 May 2026] Kaleidex group has announced plans for Kaleidex One: a major new purpose-built precision manufacturing facility in Yorkshire designed to expand the UK’s advanced medical manufacturing capabilities and support the next generation of medical device innovation.
Set to open in 2027, the 60,000 sq ft Factory of the Future will become a centre of excellence for the rapidly growing contract manufacturing organisation (CMO), bringing together advanced precision engineering, implant manufacturing, cleanroom assembly, rapid prototyping, automation, and product development under one roof.
The investment represents a significant commitment to advanced manufacturing in the North of England and reinforces the region’s growing role as a hub for high-value medical technology and engineering expertise.
Kaleidex One is being designed to support both global OEMs and emerging medical technology businesses by offering fully integrated end-to-end manufacturing solutions from concept development and prototyping through to scale-up production, finishing, sterile packing, and inspection.
The facility will introduce levels of automation rarely seen within UK medical manufacturing and is expected to strengthen the UK’s position as a globally competitive location for medtech innovation and production.
Gavin Meadows, CEO of Kaleidex group, said:
“Kaleidex One represents a major step forward not only for our business, but for the wider UK medical technology sector.
We are investing in a world-class advanced manufacturing environment that brings together cutting-edge technology, specialist expertise, and scalable production capability to help our customers accelerate innovation and bring life-enhancing products to market faster.
Yorkshire has a proud manufacturing heritage, and we believe the North of England has a critical role to play in the future of global medtech manufacturing.”
The new site will include dedicated rapid prototyping and new product introduction (NPI) cells, expanded cleanroom capacity for sterile assembly and packing, advanced finishing capabilities, automated clean lines, and enhanced quality assurance facilities.
Kaleidex One will also house the Kaleidex Academy and an Advanced Development Team skunkworks space focused on training, experimentation, and process innovation; helping develop the next generation of engineering and manufacturing talent in the region.
The company says the facility has been specifically designed to support increasing demand for implant manufacturing and scalable production for both established OEMs and high-growth medtech innovators.
The announcement comes amid growing focus on strengthening UK supply chains, expanding regional manufacturing investment, and supporting high-value industries through innovation-led growth.
Further details on Kaleidex One will be shared throughout 2026 ahead of the facility opening in 2027.
ENDS
About Kaleidex
Kaleidex is a leading Contract Manufacturing Organisation (CMO) specialising in the design, development, and production of precision-engineered medical devices. With a strong commitment to innovation and collaboration, Kaleidex, backed by private equity firm Ansor, acquires and integrates high-performing medical manufacturing companies, building a network of expertise and innovation to drive industry advancements.
For more information about Kaleidex One visit: www.kaleidexgroup.com/kaleidex-one
Editors’ notes
For more information, photography and interview requests please contact media@kaleidexgroup.com